AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$ABUS

Nguyen Tuan sold (to issuer) $240K of ABUS

Nguyen Tuan (Chief Financial Officer) sold (to issuer) 48,081 shares of Arbutus Biopharma Corp (ABUS) at $5.00 ($0.24M total) on 2026-10-01.

Original reporting
SEC EDGAR · Nguyen Tuan
Published Oct 7, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ABUS
Neutral
medium confidence
Mentioned
$ABUS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ABUSNeutralLow
01

Why it matters

The CFO's sale is modest and unlikely to affect price materially, but traders may watch for any pattern of insider selling.

02

Market read

A small insider sale with limited trading relevance; primarily of interest to insiders and compliance monitors.

03

What to watch

The CFO's remaining stake remains sizable, indicating continued confidence.

Relevance 4/10Novelty 4/10Timing: after-hours filing on Oct 7

Background

Form 4 filings disclose insider transactions and are monitored for potential signals about company outlook.

Company-level read

Ticker impact

$ABUSNeutralMedium confidence
Context

CFO Nguyen Tuan sold 48,081 shares for $240,405, reducing his stake to 111,882 shares.

Expected impact

possible slight downward pressure as market digests the sale

Evidence & confidence

The transaction is a routine Form 4 filing; the amount is modest and unlikely to move the stock significantly.

Market effects

Sector

Minimal impact on the biotech sector; no broader industry signal.

Regional

Limited to US market participants tracking insider activity.

Global

Low; the filing does not affect global markets.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    Arbutus Biopharma Corp

    Biopharmaceutical company developing RNA therapeutics, ticker ABUS.

  • Executive
    Nguyen Tuan

    Chief Financial Officer of Arbutus Biopharma.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ABUS insider trading history →

Related articles

OCT 22
$ABUSHighAI 8/10

Arbutus Biopharma Clears FDA Clinical Hold on AB-101 IND

Arbutus Biopharma (ABUS) can now advance U.S. clinical trials for AB-101 after the FDA lifted its clinical hold. The oral PD-L1 inhibitor completed a Phase 1a/1b trial, showing good tolerability and some efficacy in cHBV patients. The company is evaluating next steps for development.

tradingview.com1 min
OCT 22
$ABUSHighAI 8/10

Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Other Events. EXHIBIT 99.1 Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 Inhibitor WARMINSTER, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical compa

SEC EDGAR 8-K2 min